The Data Safety Monitoring Board for the ATLAS (Adaptive Titanium-Lattice Augmentation System) study has completed its pre-planned interim analysis and recommended continuation to Phase III. The preliminary results demonstrate both efficacy and safety, supporting further development of our skeletal enhancement technology.
Key Findings
The interim analysis included data from 847 participants who have completed at least six months of follow-up:
Efficacy Outcomes
- Bone density: Average increase of 34% at augmented sites
- Load-bearing capacity: 2.8x improvement in tested regions
- Fracture resistance: Zero fractures in augmented bones despite normal activity
- Integration stability: 99.2% of implants showing optimal osseointegration
Safety Profile
- Serious adverse events: 0.7% (primarily post-surgical infections resolved with standard treatment)
- Revision surgeries: 0.4% (all due to positioning adjustments, not device failure)
- Discontinuation rate: 1.1% (most common reason: unrelated health changes)
- Quality of life scores: Improved across all measured domains
Participant Perspectives
Trial participants have reported meaningful quality of life improvements:
“I was told I’d never hike again after my accident. Eight months after the ATLAS procedure, I completed my first mountain trail in five years.” — Study Participant 287
“The strength difference is noticeable every day. Lifting, carrying, activities I’d given up… they’re all back.” — Study Participant 412
Path Forward
Based on these results, the ATLAS study will proceed as planned:
- Complete Phase II follow-up (through month 12)
- Submit Phase III protocol to regulatory authorities
- Expand enrollment for pivotal trial (target: 3,000 participants)
- Anticipated Phase III completion: 2028
Enrollment Information
Phase III enrollment is expected to open in late 2026. Individuals interested in participating should visit our trials page to register for notification when enrollment begins.
Priority consideration will be given to individuals with documented skeletal conditions affecting quality of life who have not responded adequately to conventional treatments.
Scientific Publication
Full interim results will be submitted for peer-reviewed publication. Preliminary data was presented at the American Society for Bone and Mineral Research annual meeting; presentation materials are available upon request.
We thank all ATLAS study participants for their courage and commitment to advancing skeletal enhancement science.